Posizolid
- Generic Name
- Posizolid
- Drug Type
- Small Molecule
- Chemical Formula
- C21H21F2N3O7
- CAS Number
- 252260-06-3
- Unique Ingredient Identifier
- 82V2M8K24R
- Background
Posizolid (AZD2563) is an oxazolidinone antibiotic. In July 2002, after completion of phase I trials in December 2001, AstraZeneca announced that they were no longer pursuing the development of Posizolid, presumably due to negative trial results (though no results were reported).
- Indication
For the treatment of gram-positive infections, including multiresistant strains.
Phase 2a EBA Trial of AZD5847
Phase 2
Completed
- Conditions
- Tuberculosis
- Interventions
- Drug: Ethambutol, isoniazid, pyrazinamide, rifampin
- First Posted Date
- 2012-01-24
- Last Posted Date
- 2018-10-15
- Target Recruit Count
- 75
- Registration Number
- NCT01516203
- Locations
- 🇿🇦
Task Clinical Research Centre, Ekurhuleni, Gauteng, South Africa
A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD5847 After Multiple Doses Over 14 Days
- First Posted Date
- 2010-05-04
- Last Posted Date
- 2010-10-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT01116258
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Study to Evaluate Safety, Tolerability and Pharmacokinetics (PK) (Including Food Effect) of Oral Doses of AZD5847 in Healthy Volunteers
- First Posted Date
- 2009-12-23
- Last Posted Date
- 2010-07-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 64
- Registration Number
- NCT01037725
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath